4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 63 | 77 | +14 |
| Shares | 19.2M | 24.7M | +5.54M (+28.9%) |
| Value | $515.1M | $541.8M | +$26.7M (+5.2%) |
New holders (22)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (8)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Alkeon Capital Management LLC | 602,225 | $16.2M |
| Perceptive Advisors LLC | 375,256 | $10.1M |
| Centiva Capital, LP | 358,863 | $7.22M |
| Millennium Management LLC | 155,258 | $4.19M |
| Soleus Capital Management, L.P. | 120,900 | $3.26M |
| Mirabella Financial Services LLP | 14,080 | $380.0K |
| Rockefeller Capital Management L.P. | 1,070 | $28.0K |
| Evolution Wealth Advisors, LLC | 145 | $4.00K |